Street Calls of the Week
CHICAGO - GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced Wednesday that its Board of Directors has declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025.
The dividend will be payable on November 14, 2025, to shareholders of record as of October 24, 2025, according to a press release from the company.
GE HealthCare, which describes itself as a global healthcare solutions provider, offers medical technology, pharmaceutical diagnostics, and AI-enabled solutions. The company operates through its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses. As a prominent player in the Healthcare Equipment & Supplies industry, the company maintains strong profitability metrics with a gross margin of 41.56%. According to InvestingPro analysis, the stock currently trades at an attractive P/E ratio of 15.12x relative to its growth potential.
The company reported annual revenue of $19.7 billion and employs approximately 53,000 people worldwide. With a market capitalization of $33.8 billion and analyst price targets ranging from $73 to $106, InvestingPro’s Fair Value analysis suggests the stock is currently undervalued.
In other recent news, GE HealthCare has announced an agreement to acquire icometrix, a company specializing in AI-powered brain imaging analysis for neurological disorders. This acquisition is part of GE HealthCare’s strategy to enhance its neurological care offerings, particularly in areas like Alzheimer’s disease, as the demand for MRI in personalized treatment planning increases. Financial details of the acquisition have not been disclosed, but the company plans to use its cash reserves, which stood at $3.8 billion at the end of Q2 2025, to fund the transaction.
Additionally, GE HealthCare is exploring strategic options for its China operations, which may include selling a stake in the unit. The company is working with advisers to evaluate various scenarios, including selling the entire unit, finding a local partner, or divesting a partial stake. Meanwhile, BNP Paribas Exane has reiterated its Outperform rating for GE HealthCare, maintaining a price target of $92.00 following the company’s acquisition plans aimed at bolstering its neuro solutions portfolio.
In a separate development, GE HealthCare has entered an exclusive licensing agreement with Lantheus Holdings for the prostate cancer diagnostic imaging agent, piflufolastat F18, in Japan. Under this agreement, GE HealthCare will develop, manufacture, and commercialize the agent, marking a significant step in expanding its diagnostic capabilities in the region.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.